
New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

Scott A. Wilke, MD, PhD, an assistant professor of psychiatry and the Penske Family Chair in Neuromodulation at UCLA Health.

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

In a Q&A, psychiatrist Scott Wilke, MD, explains how accelerated TMS protocols are reshaping depression care and may help tailor treatment to specific neural circuits.